CompuMed
This article was originally published in The Gray Sheet
Executive Summary
Inks deal with Merck & Co. under which it gains rights to incorporate OsteoGram software enhancements developed by Merck into the digital OsteoView 2000 bone densitometer, which is under development at CompuMed and intended for use in detecting osteoporosis and arthritis. In March, CompuMed regained exclusive worldwide rights to the OsteoGram bone density test after licensing them to Merck in 1995 ("The Gray Sheet" Sept. 4, 1995, In Brief). Merck has "invested substantial resources" in the assets related to OsteoGram, CompuMed says, including software enhancements, laboratory equipment, regulatory and clinical work products, intellectual property rights, copyrights, trademarks, marketing materials and artwork, all of which are covered under the agreement...
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.